CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
4d Molecular Therapeutics Inc   (FDMT)
Other Ticker:  
 

4d Molecular Therapeutics Inc 's Tangible Leverage Ratio

FDMT's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth


Due to net new borrowings of 15.79%, Tangible Leverage Ratio fell to 0.1, below the 4d Molecular Therapeutics Inc 's average Tangible Leverage Ratio.

Within Biotechnology & Pharmaceuticals industry in the third quarter 2023, 16 other companies have achieved lower Tangible Leverage Ratio than 4d Molecular Therapeutics Inc in the III Quarter 2023. While Tangible Leverage Ratio total ranking has improved so far in the third quarter 2023 to 199, from total ranking in the second quarter 2023 at 200 .

Explain Tangible Leverage Ratio?
What is FDMT Market Share?
What are FDMT´s Total Liabilities?


FDMT Tangible Leverage Ratio (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter
Y / Y Tangible Equity Change 31.22 % 19.31 % -26.16 % -27.5 % 12.18 %
Y / Y Total Liabilities Change 10.3 % -10.06 % -11.97 % -11.26 % 74.23 %
Tangible Leverage Ratio MRQ 0.1 0.08 0.12 0.13 0.11
FDMT's Total Ranking # 199 # 200 # 305 # 361 # 339
Seq. Tangible Equity Change 1.47 % 48.74 % -5.5 % -8 % -7.73 %
Seq. Total Liabilities Change 15.79 % 7.65 % -16.7 % 6.23 % -5.59 %

New: More FDMT's historic Tangible Leverage Ratio results >>


Tangible Leverage Ratio third quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 17
Healthcare Sector # 95
Overall Market # 199


Tangible Leverage Ratio Statistics
High Average Low
0.13 0.1 0.06
(Dec 31 2022)   (Jun 30 2021)




Financial Statements
4d Molecular Therapeutics Inc 's Tangible Equity $ 330 Millions Visit FDMT's Balance sheet
4d Molecular Therapeutics Inc 's Total Liabilities $ 32 Millions Visit FDMT's Balance sheet
Source of FDMT's Sales Visit FDMT's Sales by Geography


Cumulative 4d Molecular Therapeutics Inc 's Tangible Leverage Ratio

FDMT's Tangible Leverage Ratio for the trailling 12 Months

FDMT Tangible Leverage Ratio

 (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter
Y / Y Tangible Equity TTM Growth 31.22 % 19.31 % -26.16 % -27.5 % 12.18 %
Y / Y Total Liabilities TTM Growth 10.3 % -10.06 % -11.97 % -11.26 % 74.23 %
Tangible Leverage Ratio TTM 0.1 0.11 0.12 0.11 0.11
Total Ranking TTM # 155 # 123 # 2 # 170 # 249
Seq. Tangible Equity TTM Growth 1.47 % 48.74 % -5.5 % -8 % -7.73 %
Seq. Total Liabilities TTM Growth 15.79 % 7.65 % -16.7 % 6.23 % -5.59 %

FDMT Company Profile >> Back to FDMT Financial Strength Comparisons >> See FDMT Balance Sheets

On the trailing twelve months basis Despite of the net new borrowings of 15.79% during the twelve months period ending in III Quarter 2023 4d Molecular Therapeutics Inc has managed to decrease Tangible Leverage Ratio in the III Quarter 2023 to 0.1, below 4d Molecular Therapeutics Inc 's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry 16, during the past 12 months, other companies have achieved lower Tangible Leverage Ratio than 4d Molecular Therapeutics Inc . While Tangible Leverage Ratio total ranking has deteriorated during the twelve months ending in the III Quarter 2023, compared to the prior period, from 123 to 155.

Explain Tangible Leverage Ratio?
What is FDMT Market Share?
What are FDMT´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 17
Healthcare Sector # 95
Within the Market # 155


trailing twelve months Tangible Leverage Ratio Statistics
High Average Low
0.13 0.1 0.06
(Dec 31 2022)   (Jun 30 2021)




Companies with similar Tangible Leverage Ratio in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Tangible Leverage RatioSep 30 2023 MRQ Total LiabilitiesSep 30 2023 MRQ Tangible Equity
Tarsus Pharmaceuticals Inc   0.26 $ 54.668  Millions$ 209.697  Millions
Vor Biopharma Inc   0.25 $ 44.499  Millions$ 174.781  Millions
Titan Pharmaceuticals Inc   0.23 $ 1.866  Millions$ 8.133  Millions
Hillevax Inc   0.23 $ 68.339  Millions$ 298.630  Millions
Vir Biotechnology Inc   0.23 $ 369.810  Millions$ 1,632.691  Millions
Ocugen Inc   0.22 $ 13.128  Millions$ 58.395  Millions
Allogene Therapeutics inc   0.22 $ 129.224  Millions$ 583.102  Millions
Aim Immunotech Inc   0.22 $ 4.509  Millions$ 20.448  Millions
Dyadic International Inc  0.21 $ 1.603  Millions$ 7.653  Millions
Replimune Group Inc   0.21 $ 97.226  Millions$ 465.172  Millions
Crispr Therapeutics Ag  0.21 $ 359.036  Millions$ 1,727.764  Millions
Voyager Therapeutics Inc   0.21 $ 36.346  Millions$ 176.220  Millions
Dbv Technologies S a   0.19 $ 28.027  Millions$ 143.930  Millions
Athira Pharma Inc   0.19 $ 29.936  Millions$ 154.764  Millions
Fresh Tracks Therapeutics Inc   0.19 $ 2.108  Millions$ 10.949  Millions
Inhibikase Therapeutics Inc   0.19 $ 2.863  Millions$ 15.018  Millions
Finch Therapeutics Group Inc   0.19 $ 4.879  Millions$ 25.813  Millions
Surrozen Inc   0.19 $ 8.442  Millions$ 45.531  Millions
Palisade Bio Inc   0.19 $ 2.609  Millions$ 14.082  Millions
Aura Biosciences Inc   0.18 $ 28.048  Millions$ 151.718  Millions
Springworks Therapeutics Inc   0.18 $ 72.755  Millions$ 394.899  Millions
In8bio Inc   0.18 $ 3.188  Millions$ 17.758  Millions
Prime Medicine Inc   0.18 $ 33.969  Millions$ 193.957  Millions
Tenaya Therapeutics Inc   0.17 $ 28.513  Millions$ 164.884  Millions
Jasper Therapeutics Inc   0.17 $ 16.272  Millions$ 94.133  Millions
Vigil Neuroscience Inc   0.17 $ 23.320  Millions$ 135.836  Millions
Anavex Life Sciences Corp   0.17 $ 24.151  Millions$ 141.852  Millions
Relay Therapeutics Inc   0.17 $ 128.586  Millions$ 776.073  Millions
Immunovant Inc   0.16 $ 39.645  Millions$ 251.811  Millions
Turnstone Biologics Corp   0.15 $ 17.413  Millions$ 113.899  Millions

Date modified: 2023-11-12T11:21:21+00:00



Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com